bioAffinity Technologies, Inc. has announced its participation in the upcoming CHEST 2026 event, where it will sponsor a Learning Theater presentation. This event is significant as it showcases the company's innovative CyPath Lung® technology, which aims to improve lung cancer risk stratification and the management of pulmonary nodules in high-risk patients.
The presentation will also discuss bioAffinity's positive research findings related to a new test that measures asthma and COPD-related lung inflammation, as well as drug-related receptors. This development aligns with the company's focus on enhancing diagnostic tools and treatment options in the healthcare sector.
Background
bioAffinity Technologies, Inc. is a Delaware-based company engaged in commercial physical and biological research, categorized under SIC 8731. The company trades on the Nasdaq under the ticker symbols BIAF and BIAFW. Recent filings indicate that bioAffinity is an emerging growth company, which allows it to take advantage of certain regulatory exemptions as it continues to develop its technologies.
What the Filing Says
In the filing dated October 15, 2026, bioAffinity Technologies stated, "On October 15, 2026, bioAffinity Technologies, Inc. issued a press release announcing that it will sponsor a Learning Theater presentation at CHEST 2026... The presentation will include discussion of the Company’s positive research data in the development of its new test measuring asthma and COPD-related lung inflammation and drug-related receptors." This highlights the company's ongoing commitment to advancing lung health diagnostics.
Impact
This announcement may affect various stakeholders, including healthcare professionals, patients at risk for lung cancer, and investors interested in the advancements of bioAffinity Technologies. The focus on innovative diagnostic solutions could position the company favorably within the competitive landscape of the commercial physical and biological research industry.
What's Next
Following this announcement, it is expected that bioAffinity Technologies will continue to engage with the medical community and present further developments at industry events. The filing does not specify what additional steps the company will take post-presentation.